Drugs that contain Panobinostat Lactate
1. Farydak patents expiration
FARYDAK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6552065 | SECURA | Deacetylase inhibitors |
Aug, 2021
(2 years ago) | |
| US6833384 | SECURA | Deacetylase inhibitors |
Sep, 2021
(2 years ago) | |
| US7989494 | SECURA | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide |
Jan, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7067551 | SECURA | Deacetylase inhibitors |
Aug, 2021
(2 years ago) | |
| US8883842 | SECURA | Use of HDAC inhibitors for the treatment of myeloma |
Jun, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 23, 2020 |
| Orphan Drug Exclusivity(ODE) | Feb 23, 2022 |
| Orphan Drug Exclusivity(ODE-89) | Feb 23, 2022 |
NCE-1 date: 23 February, 2019
Market Authorisation Date: 23 February, 2015
Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone
Dosage: CAPSULE;ORAL
More Information on Dosage
FARYDAK family patents
